Answers are grounded in this paper and cite their sources.
This study analyzes the European Union's (EU's) regulatory practices of Herbal Medicinal Products (HMPs), aiming to provide implications for Traditional Chinese Medicines (TCMs) registration process within the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). This paper conducts a comparative analysis of the regulatory agencies, legal frameworks, registration classifications, market authorization procedures, and the number of applications and approvals for both HMPs in the EU and TCMs in the GBA, thereby identifying the distinctive regulatory features across these regions. Our study finds that the EU has established a scientific, efficient, and harmonized regulation system for HMPs, whereas the registration of TCMs in the GBA is characterized by complexity and jurisdictional disparities in requirements and procedures. Drawing on the EU's advanced regulatory practices, the study offers recommendations to enhance the mutual recognition and accessibility of TCMs within the GBA. This study offers a comprehensive understanding of the EU's HMPs regulation and the GBA's TCMs registration, contributing to the synergistic development of TCMs in the GBA.
No takes yet. Share an insight, caveat, or question.
Ran et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: